Abstract
Whether or not the topic of the Oncology Drug Advisory Committee (ODAC) sounds interesting or not, no one can afford not to read every word written on the subject, because the role of the ODAC in the review process for oncological products is often misunderstood. The role of the ODAC is simple, but the expectations for the committee’ s performance range from the misconception that the ODAC approves drugs to the lack of confidence that ODAC impacts Food and Drug Administration (FDA) decisions.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Vaccari, L.A. (2004). The Role of the Oncology Drug Advisory Committee in the FDA Review Process for Oncologic Products. In: Teicher, B.A., Andrews, P.A. (eds) Anticancer Drug Development Guide. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-739-0_22
Download citation
DOI: https://doi.org/10.1007/978-1-59259-739-0_22
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4684-9841-7
Online ISBN: 978-1-59259-739-0
eBook Packages: Springer Book Archive